logo BDSP

Base documentaire

  1. Fulltext. Non-ventilatory treatment of acute hypoxic respiratory failure.

    Article - En anglais


    Severe acute hypoxic respiratory failure is uncommon but often fatal.

    Standard treatment involves high inspired oxygen concentrations, mechanical ventilation and positive end-expiratory pressure.

    Many other interventions have been used in parallel with conventional treatment or as rescue therapy when it fails, including extracorporeal gas exchange, prone positioning, inhaled vasodilators, exogenous surfactants and drugs which modify the inflammatory process.

    Nearly all these treatments improve arterial oxygenation or markers of lung injury.

    However, the relationship between oxygenation and survival in acute hypoxaemic respiratory failure is not established, so improved oxygenation cannot be used as a surrogate for survival.

    Randomised controlled trials are, therefore, needed to assess the effects of these treatments on mortality.

    In such trials, extracorporeal oxygenation and extracorporeal carbon dioxide elimination, surfactant, early methylprednisolone, and prostaglandin E1 offer no survival advantage over conventional therapy.

    Prophylactic ketoconazole and pentoxifylline appear to improve mortality in small studies in surgical and oncology patients respectively, and methylprednisolone improves mortality and morbidity in unresolving disease.

    Mots-clés Pascal : Insuffisance respiratoire, Aigu, Hypoxie, Prévalence, Protocole thérapeutique, Etude comparative, Kétoconazole, Prévention, Association médicamenteuse, Pentoxifylline, Evaluation, Amélioration, Mortalité, Article synthèse, Homme, Appareil respiratoire pathologie, Antifongique, Imidazole dérivé, Vasodilatateur, Xanthine dérivé, Inhibiteur enzyme, 2',3'-Cyclic-nucleotide 3'-phosphodiesterase, Phosphoric diester hydrolases, Esterases, Hydrolases, Enzyme

    Mots-clés Pascal anglais : Respiratory failure, Acute, Hypoxia, Prevalence, Therapeutic protocol, Comparative study, Ketoconazole, Prevention, Drug combination, Pentoxifylline, Evaluation, Improvement, Mortality, Review, Human, Respiratory disease, Antifungal agent, Imidazole derivatives, Vasodilator agent, Xanthine derivatives, Enzyme inhibitor, 2',3'-Cyclic-nucleotide 3'-phosphodiesterase, Phosphoric diester hydrolases, Esterases, Hydrolases, Enzyme

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 99-0346656

    Code Inist : 002B27B02. Création : 14/12/1999.